ImmuCell Corporation
ICCC
$9.77
-$0.15-1.46%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.50% | 28.39% | -1.61% | -8.41% | 17.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.50% | 28.39% | -1.61% | -8.41% | 17.76% |
| Cost of Revenue | 30.93% | 20.93% | -4.14% | -29.02% | -14.51% |
| Gross Profit | -13.51% | 38.86% | 2.78% | 49.22% | 129.00% |
| SG&A Expenses | 68.20% | 60.22% | 1.32% | 20.14% | -10.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.62% | 20.70% | -3.45% | -16.71% | -14.35% |
| Operating Income | 239.69% | 76.21% | 19.41% | 103.50% | 141.08% |
| Income Before Tax | 273.28% | 34.87% | -646.64% | 80.68% | 132.92% |
| Income Tax Expenses | 2,321.05% | 557.89% | -45.00% | 246.15% | 46.15% |
| Earnings from Continuing Operations | 265.55% | 34.18% | -653.65% | 80.09% | 132.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 265.55% | 34.18% | -653.65% | 80.09% | 132.77% |
| EBIT | 239.69% | 76.21% | 19.41% | 103.50% | 141.08% |
| EBITDA | 94.34% | 39.25% | 11.83% | 597.80% | 272.97% |
| EPS Basic | 264.03% | 33.21% | -646.88% | 82.07% | 128.35% |
| Normalized Basic EPS | 277.03% | 88.39% | 26.30% | 90.67% | 128.36% |
| EPS Diluted | 259.71% | 31.25% | -646.88% | 77.78% | 127.80% |
| Normalized Diluted EPS | 271.80% | 88.39% | 24.38% | 90.67% | 128.36% |
| Average Basic Shares Outstanding | 0.37% | 0.73% | 1.24% | 10.80% | 15.64% |
| Average Diluted Shares Outstanding | 1.75% | 0.73% | 2.86% | 10.80% | 15.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |